Clinical Trial Detail

NCT ID NCT03516279
Title Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

chronic myeloid leukemia

Therapies

Nilotinib + Pembrolizumab

Dasatinib + Pembrolizumab

Imatinib + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.